Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 7,329

Document Document Title
WO/2006/029436A1
The invention relates to the compounds of the general formula (I), wherein X = -CH- or -N=, n = 0 or 1, R1 = -H, -F, -OCH3 or -COOCH3, R2 = -H or -F, R3 = -H, or R2 and R3 together represent -CH2-CH2-, R4 = -H or -OCH3, R5 = -H, -OCH3 or...  
WO/2006/027454A1
The invention relates to compounds of formula (I): where X + Y = keto, or X = OH and Y =H, or X + Y = oxime or methyloxime, B = OH and C + D =H, or C + D = C1-C4 linear or branched alkyl, or C = H and D = C1-C4 linear or branched alkyl, ...  
WO/2006/029135A1
A process for preparing indanylamine and aminotetralin derivatives from indanone or tetralone oximes by acylating the oximes with an organic anhydride, followed by catalytic hydrogenation in the presence of an organic anhydride with subs...  
WO/2006/028006A1
Disclosed is a near infrared absorbing compound which does not contain antimony or arsenic and has excellent stability, especially excellent heat resistance, light resistance and wet heat resistance. Also disclosed are a near-infrared ab...  
WO/2006/026251A1
The subject invention provides compounds which are easily metabolized by the metabolic drug detoxification systems. Particularly, fluvoxamine analogs which have been designed to include esters within the structure of the compounds are ta...  
WO2005079774A3
A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short­circuits the visual cycle at a step of the visual cycle that occurs o...  
WO/2006/016248A1
The present invention relates to a delivery system in the form of a dynamic mixture obtained by reacting together, in the presence of water, at least one hydrazine derivative with at least one perfuming, flavoring, insect repellent or at...  
WO2005118511A3
Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are biphenyls and rela...  
WO/2006/015200A1
The present invention relates to novel 1,3-diimines and 1,3-diimine copper complexes and the use of 1,3-diimine copper complexes for the deposition of copper on substrates or in or on porous solids in an atomic layer deposition process.  
WO/2006/011669A1
Novel cinnamic acid-related compounds and salts thereof which are useful as drugs, specifically, compounds represented by the general formula [1] and salts thereof: [1] wherein A is a six-membered hydrocarbon ring or a six-membered heter...  
WO/2006/010598A1
The invention relates to a category of non-glycosidic and non-peptidic select inhibitors of general formula (1), with a low molecular weight, and to a method for the production thereof. Said category is a category of non-toxic select inh...  
WO/2006/010094A1
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal depositi...  
WO/2006/003795A1
A process which comprises using a stable Ru(salen)(CO) complex represented by the general formula (I) or an enantiomer thereof as the catalyst and by which optically active aziridines and amines can be produced enantioselectively with a ...  
WO2005066115A3  
WO/2006/000293A1
The invention relates to the novel ortho-substituted (3-hydroxyphenyl)-acetic acid benzylidene hydrazides of formula (I), wherein R1 to R9 are defined as in claim 1. Said novel compounds are SGK inhibitors and can be used in the treatmen...  
WO/2006/001537A1
A process for producing a hydrazone compound represented by the general formula (5) which comprises the step of condensing a hydrazine compound represented by the general formula (3) with a carbonyl compound represented by the general fo...  
WO/2006/000836A1
A process for the preparation of anastrozole.  
WO/2005/123668A1
The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another ...  
WO2005085189A3
The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein X is selected from (II) and (III), Y is selected from SO2NH, CONH, CH=N, CH2NH and CH=CH; R<1-5 >are each independently sele...  
WO/2005/121074A2
The invention relates to processes for the preparation of Schiff's base, and to the use of Schiff's base as intermediate in the preparation of naphthalenamine derivatives which are active compounds for treating the anxiety related disord...  
WO2005034940A3
The invention relates to substances, which specifically inhibit both Ala-p-nitroanilide-cleaving peptidases as well as Gly-Pro-p-nitroanilide-cleaving peptidases, for use in the field of medicine. The invention also relates to the use of...  
WO/2005/113487A2
The invention is directed to novel compounds that are used in the formation of polyurea compositions, including one-part and two-part polyurea compositions. The invention is also directed to polyureas formed from such compounds, cross-li...  
WO/2005/110975A1
The invention relates to substituted cyclohexyl-1,4-diamine derivatives, to a method for their production, to medicaments containing said compounds and to the use of substituted cyclohexyl-1,4-diamine derivatives for producing medicaments.  
WO/2005/105734A1
Novel unsymmetrical diimines containing a polar group are made by preparing a mixture of the unsymmetrical diimine and two symmetrical diimines, for example by reacting a dicarbonyl compound with two primary amines. The unsymmetrical dii...  
WO/2005/105764A1
Compounds of the formula (I): in which R, R1 and R2 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and . processes for the...  
WO/2005/105896A1
The invention relates to a molecule comprising at least one carbon-carbon double bond which is substituted by at least one cyclopentadienyl-metal-cyclopentadienyl complex, having the cis/trans isomerisation property, in a reversible mann...  
WO2005066115A8
Compounds of the formula where the variables have the values described in the specification are antagonists of RAR
WO/2005/100303A1
The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and...  
WO2005066116A8
Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RARga...  
WO/2005/094805A1
A medicine having prostaglandin D2 (PGD2) production inhibitory activity and having as an active ingredient a substance selected from compounds represented by the general formula (I): A-Y-B &lcub wherein A and B each independently repres...  
WO/2005/095330A1
Formula (I), wherein X represents a group -O-A1- or a group -N=A2-, Y represents a single bond, O or S, or X and Y together may represent O, Q represents an aryl group that may be optionally substituted, a heterocyclic group that may be ...  
WO/2005/093004A1
Disclosed are an agent and method for controlling gelation which are capable of completely controlling the fluidity of a fluid compound. Specifically disclosed is a gelation controlling agent which is added to a fluid compound for transf...  
WO/2005/085183A1
The invention relates to a method of preparing benzazepine compounds having general formula (IA) consisting in reacting at least one compound having general formula (IIA) with an olefin, the compound thus obtained then being cyclised suc...  
WO/2005/085216A1
An isoxazoline-substituted benzamide compound of the general formula: (1) [wherein each of A1, A2 and A3 independently represents a carbon atom or nitrogen atom; G a benzene ring, etc.; W an oxygen atom or sulfur atom; X a halogen atom, ...  
WO/2005/085174A1
Disclosed is a method for producing an optically active 1-aryl-2-fluoro-substituted ethylamine represented by the following general formula [2]: [wherein Ar represents an aryl group; n represents an integer of 1 or 2; and * represents an...  
WO/2005/085189A2
The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein X is selected from (II) and (III), Y is selected from SO2NH, CONH, CH=N, CH2NH and CH=CH; R1-5 are each independently select...  
WO/2005/082882A1
The invention relates to compounds of general formula (I), where R1 and R2 are independently selected from a hydrogen atom, a branched or straight chain alkyl with 1 to 6 carbon atoms, a fluoroalkyl group with 1 to 6 carbon atoms and 3 t...  
WO/2005/082956A1
Disclosed is a photosensitive resin composition used for interlayer insulating films or surface protection films which has excellent resolution and can be developed with an aqueous alkaline solution. The photosensitive resin composition ...  
WO/2005/082841A1
The present invention relates to immunosuppressants, processes for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of d...  
WO/2005/080327A1
Disclosed are compounds of Formula I, and their N-oxides and suitable salts thereof, which are useful for controlling invertebrate pests. I wherein Q is Q-1 or Q-2; Y is H, F, Cl or CH3; A is CN, C1-C6 alkyl, ORla, SRla, NRlaR2a or CONR1...  
WO2005063665B1
The invention provides para substituted dialkylphenol derivatives of propofol. The invention further provides pharmaceutical compositions comprising such analogs, methods for preparing such analogs, and methods of using such analogs to i...  
WO2005037772A3
The invention relates to novel compounds of general formula (I), compositions containing said compounds and to the use thereof for producing pharmaceutical compositions used for human medicine or for veterinary science, and also for cosm...  
WO/2005/079863A1
It is intended to provide a contrast medium for thrombus formation capable of binding specifically to a thrombus, lowering background noise and thus improving the resolution in a contrast examination for thrombus formation; and a method ...  
WO/2005/079774A2
A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short­circuits the visual cycle at a step of the visual cycle that occurs o...  
WO/2005/075501A1
A process for forming a conjugate of a polyoxyalkylene polymer (such as polyethylene glycol) with a compound containing an amine group(s) and/or a sulfide group(s) by reacting the compound with an acrylate terminated polyoxyalkylene (suc...  
WO/2005/073196A1
A compound of the following formula (I). This compound (I) can be produced by reacting a 1,1'-binaphthyl 2,2'-dimethylenebromide derivative which can be produced through a relatively small number of steps with an easily available seconda...  
WO2005000233A3
The present invention is directed to compounds having the structure (I) wherein R1, R2, R3, R4, R5 and m are as defined herein. The compounds of this invention are novel therapeutic agents for the treatment of cancer, metabolic diseases ...  
WO/2005/068415A1
Disclosed is a phenylalanine derivative having excellent VLA-4 inhibitory activity which is represented by the following general formula (1) or a salt thereof. (1) (In the formula, R1 represents an aromatic hydrocarbon group having 6-10 ...  
WO/2005/066116A1
Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR&g...  
WO/2005/066115A2
Compounds of the formula where the variables have the values described in the specification are antagonists of RAR&gammad retinoid receptors.  

Matches 651 - 700 out of 7,329